Two tests and one reference [General Sta­tis­tics]

posted by Brus – Spain, 2020-08-31 09:58 (251 d 00:36 ago) – Posting: # 21895
Views: 3,644

Dear Helmut and all,

If one test and two references of different regions are tested in a bioequivalence study, is it necessary a α adjustment?

In my case, we want to demonstrate if the test product is bioequivalent to R1 (European product reference) or if test product is bioequivalent to R2 (Reference product in the United Kingdom).

If I have not misunderstood, in this case, alpha should be penalized, even if they are from different regions and to market in different regions because of the word "OR"?

Is there a way to not penalize alpha? If the "O" is changed to "AND"? Executing two different clinical trials (one for Europe and one for the UK)?

Best regards,

Complete thread:

Activity
 Admin contact
21,445 posts in 4,482 threads, 1,510 registered users;
online 21 (0 registered, 21 guests [including 5 identified bots]).
Forum time: Sunday 10:35 CEST (Europe/Vienna)

It is better to know some of the questions
than all of the answers.    James Thurber

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5